

# CENTER FOR DRUG EVALUATION AND RESEARCH

## Approval Package for:

### *APPLICATION NUMBER:*

**212156Orig1s000**

*Trade Name:* Micafungin for Injection

*Generic or Proper Name:* micafungin

*Sponsor:* Par Sterile Products, LLC

*Approval Date:* June 16, 2021

*Indication:*

- Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older
- Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older
- Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing Hematopoietic Stem Cell Transplantation (HSCT)

# CENTER FOR DRUG EVALUATION AND RESEARCH

## 212156Orig1s000

### CONTENTS

#### Reviews / Information Included in this NDA Review.

<b>Approval Letter</b>	<b>X</b>
<b>Other Action Letters</b>	<b>X</b>
<b>Labeling</b>	<b>X</b>
<b>REMS</b>	
<b>Summary Review</b>	<b>X</b>
<b>Officer/Employee List</b>	<b>X</b>
<b>Office Director Memo</b>	
<b>Cross Discipline Team Leader Review</b>	<b>X</b>
<b>Clinical Review(s)</b>	
<b>Product Quality Review(s)</b>	<b>X</b>
<b>Non-Clinical Review(s)</b>	<b>X</b>
<b>Statistical Review(s)</b>	
<b>Clinical Microbiology / Virology Review(s)</b>	
<b>Clinical Pharmacology Review(s)</b>	
<b>Other Reviews</b>	<b>X</b>
<b>Risk Assessment and Risk Mitigation Review(s)</b>	
<b>Proprietary Name Review(s)</b>	
<b>Administrative/Correspondence Document(s)</b>	<b>X</b>

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**212156Orig1s000**

**APPROVAL LETTER**

NDA 212156

**NDA APPROVAL**

Par Sterile Products, LLC  
Attention: Carla English  
Director, Regulatory Affairs  
Six Ram Ridge Road  
Chestnut Ridge, NY 10977

Dear Ms. English:

Please refer to your new drug application (NDA) dated July 18, 2019, received July 18, 2019, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Micafungin for Injection, 50 mg/vial and 100 mg/vial.

We acknowledge receipt of your amendment dated December 21, 2020, which constituted a complete response to our May 18, 2020, action letter.

This NDA provides for the use of Micafungin for Injection, 50 mg/vial and 100 mg/vial for the following indications:

- Treatment of candidemia, acute disseminated candidiasis, *Candida* peritonitis and abscesses in adult and pediatric patients 4 months of age and older;
- Treatment of esophageal candidiasis in adult and pediatric patients 4 months of age and older;
- Prophylaxis of *Candida* infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation (HSCT).

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using

the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

### **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 212156.**” Approval of this submission by FDA is not required before the labeling is used.

### **DATING PERIOD**

Based on the stability data submitted to date, the expiry dating period for Micafungin for Injection shall be 24 months from the date of manufacture when stored at 20°C to 25°C.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **PROPRIETARY NAME**

If you intend to have a proprietary name for this product, the name and its use in the labeling must conform to the specifications under 21 CFR 201.10 and 201.15. We recommend that you submit a request for a proposed proprietary name review. (See the

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

guidance for industry *Contents of a Complete Submission for the Evaluation of Proprietary Names*, and *PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2018 through 2022*.)

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup>

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Eva Zuffova, MS, PhD, Regulatory Project Manager, at (301) 796-0697.

Sincerely,

*{See appended electronic signature page}*

Dmitri Iarikov, MD, PhD  
Deputy Director  
Division of Anti-Infectives  
Office of Infectious Diseases  
Center for Drug Evaluation and Research

### **ENCLOSURE(S):**

- Content of Labeling
  - Prescribing Information
- Carton and Container Labeling

---

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/media/128163/download>.

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

DMITRI IARIKOV  
06/16/2021 02:06:49 PM